These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 11177313)

  • 1. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
    Jover JA; Hernández-García C; Morado IC; Vargas E; Bañares A; Fernández-Gutiérrez B
    Ann Intern Med; 2001 Jan; 134(2):106-14. PubMed ID: 11177313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.
    Caporali R; Cimmino MA; Ferraccioli G; Gerli R; Klersy C; Salvarani C; Montecucco C;
    Ann Intern Med; 2004 Oct; 141(7):493-500. PubMed ID: 15466766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al.
    Jover JA; Hernández-Garcia C; Morado IC; Vargas E; Bañares A; Fernandez-Gutierrez B
    Arthritis Rheum; 2003 Apr; 48(4):1158-9. PubMed ID: 12687561
    [No Abstract]   [Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
    Hoffman GS; Cid MC; Hellmann DB; Guillevin L; Stone JH; Schousboe J; Cohen P; Calabrese LH; Dickler H; Merkel PA; Fortin P; Flynn JA; Locker GA; Easley KA; Schned E; Hunder GG; Sneller MC; Tuggle C; Swanson H; Hernández-Rodríguez J; Lopez-Soto A; Bork D; Hoffman DB; Kalunian K; Klashman D; Wilke WS; Scheetz RJ; Mandell BF; Fessler BJ; Kosmorsky G; Prayson R; Luqmani RA; Nuki G; McRorie E; Sherrer Y; Baca S; Walsh B; Ferland D; Soubrier M; Choi HK; Gross W; Segal AM; Ludivico C; Puechal X;
    Arthritis Rheum; 2002 May; 46(5):1309-18. PubMed ID: 12115238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Tocilizumab in Giant-Cell Arteritis.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
    N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vision loss in giant cell arteritis patients treated with alternate-day corticosteroids: comment on the article by Hoffman et al.
    Spiera RF; Kupersmith M; Paget S; Spiera H
    Arthritis Rheum; 2003 Apr; 48(4):1159-60; author reply 1160-1. PubMed ID: 12687562
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
    Salvarani C; Macchioni P; Manzini C; Paolazzi G; Trotta A; Manganelli P; Cimmino M; Gerli R; Catanoso MG; Boiardi L; Cantini F; Klersy C; Hunder GG
    Ann Intern Med; 2007 May; 146(9):631-9. PubMed ID: 17470831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Corticosteroid saving-up in giant cell arteritis?].
    Schnabel A
    Dtsch Med Wochenschr; 2002 Sep; 127(37):1910. PubMed ID: 12226792
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis.
    Perez-Sancristobal I; Alvarez-Hernandez P; Lajas-Petisco C; Fernandez-Gutierrez B
    Reumatol Clin (Engl Ed); 2024 Feb; 20(2):108-112. PubMed ID: 38395494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
    Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
    Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate treatment in the management of giant cell arteritis.
    Hernández-García C; Soriano C; Morado C; Ramos P; Fernández-Gutiérrez B; Herrero M; Bañares A; Jover JA
    Scand J Rheumatol; 1994; 23(6):295-8. PubMed ID: 7801052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
    Seror R; Baron G; Hachulla E; Debandt M; Larroche C; Puéchal X; Maurier F; de Wazieres B; Quéméneur T; Ravaud P; Mariette X
    Ann Rheum Dis; 2014 Dec; 73(12):2074-81. PubMed ID: 23897775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
    Hoffman GS; Cid MC; Rendt-Zagar KE; Merkel PA; Weyand CM; Stone JH; Salvarani C; Xu W; Visvanathan S; Rahman MU;
    Ann Intern Med; 2007 May; 146(9):621-30. PubMed ID: 17470830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
    Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients.
    Les I; Pijoán JI; Rodríguez-Álvarez R; Ruiz-Irastorza G; Martínez-Berriotxoa A
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-90-7. PubMed ID: 26016756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
    Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
    Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis].
    Chartaux E; Joly P
    Ann Dermatol Venereol; 2010; 137(8-9):507-13. PubMed ID: 20804893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.